Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Urogen Pharma (URGN : NSDQ)

• Company Description    UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. Number of Employees: 195

• Price / Volume Information    Yesterday's Closing Price: $5.61 Daily Weekly Monthly 20 Day Moving Average: 173,350 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 1.41 52 Week High: $19.66 52 Week Low: $5.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.54% -10.51% 12 Week -5.24% 4.17% Year To Date -41.01% -29.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 Alexander Park - Princeton,NJ 08540 USA ph: 646-768-9780 fax: - vincent.perrone@urogen.com http://www.urogen.com

• General Corporate Information    Officers Elizabeth Barrett - Chief Executive Officer Arie Belldegrun - Chairman Molly Henderson - Chief Financial Officer Cynthia Butitta - Director Fred E. Cohen - Director Peer Information Urogen Pharma (CORR.) Urogen Pharma (RSPI) Urogen Pharma (CGXP) Urogen Pharma (BGEN) Urogen Pharma (GTBP) Urogen Pharma (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M96088105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/03/22 Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: 1.41 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.81 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -6.84% vs. Previous Quarter: 1.57% Sales Growth vs. Year Ago Period: 81.22% vs. Previous Quarter: -16.14% ROE 03/31/22 - -572.49 12/31/21 - -256.66 09/30/21 - -173.25 ROA 03/31/22 - -78.96 12/31/21 - -87.69 09/30/21 - -88.93 Current Ratio 03/31/22 - 8.41 12/31/21 - 5.11 09/30/21 - 6.32 Quick Ratio 03/31/22 - 8.16 12/31/21 - 4.90 09/30/21 - 6.13 Operating Margin 03/31/22 - -209.30 12/31/21 - -230.67 09/30/21 - -283.41 Net Margin 03/31/22 - -209.30 12/31/21 - -230.67 09/30/21 - -283.41 Pre-Tax Margin 03/31/22 - -206.02 12/31/21 - -227.66 09/30/21 - -274.16 Book Value 03/31/22 - - 12/31/21 - - 09/30/21 - - Inventory Turnover 03/31/22 - 1.38 12/31/21 - 1.34 09/30/21 - 1.35 Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©